Atypical Mycobacteria After an Aesthetic Procedure

Most infections after an aesthetic procedure are common bacterial ones, appear within days and respond to appropriate treatment. Some, however, depart from the script: they appear late, look like a reaction to the material, improve and worsen, and do not respond to the usual antibiotic. In those situations, one hypothesis has to be on the professional's mind: atypical mycobacteria.

This text is a review focused on safety. It does not prescribe treatment, which belongs to the infectious disease physician or the treating professional, nor does it replace an in-person assessment. The goal is to recognize the pattern, act quickly on referral and reinforce prevention. The general overview of infection is in infection and biofilm after filler.

What are atypical mycobacteria?

They are nontuberculous mycobacteria, found in the environment, in water, soil and on surfaces. They do not cause tuberculosis, but they can infect the skin and subcutaneous tissue when they enter through a puncture with contaminated material or in a contaminated environment. Some grow quickly in culture, others slowly.

Three characteristics explain the clinical difficulty:

1. Indolent course. The picture appears late and progresses slowly, which delays suspicion.
2. Resistance. Many species are resistant to common antibiotics, and treatment requires specific regimens.
3. Granuloma formation. The body's response can resemble a foreign body reaction, which confuses the diagnosis with a material-related granuloma.

It is not a frequent finding, but it is a diagnosis to keep in mind. Cases described in the literature link the problem to asepsis failures, use of contaminated solutions, non-sterile water and uncontrolled reprocessed materials.

How does the picture usually present?

The picture depends on the area and the procedure, but some findings appear often.

The interval between the procedure and onset is usually weeks to months, which makes it hard to link cause and effect. The patient often does not even connect the lesion to the procedure and goes to another service.

Compare with the acute pictures described in abscess after filler and facial cellulitis after a procedure, which have a faster onset and a more predictable response. The differential diagnosis also includes nodules after biostimulator and delayed inflammatory reaction to filler.

What are the sources of contamination?

In most described cases, the cause lies in the process, not in the patient.

• Asepsis failure, with inadequate skin antisepsis or a break in aseptic technique (see chlorhexidine in facial antisepsis).
• Contaminated solutions and water, used to dilute, clean or prepare.
• Poorly reprocessed materials, when there is reuse without control (see sterilization of reusable materials).
• Multidose vials handled without rigor.
• Inadequate environment, with insufficient cleaning of surfaces.
• Procedures outside an appropriate setting, without a biosafety workflow.

This does not mean every case is the professional's failure. But it does mean prevention depends on what is under your control: process, material, environment and records.

How do you suspect it and what do you do?

If a patient has a late lesion that does not subside, step-by-step reasoning helps.

1. Listen and examine. When it started, what was done before, whether there was prior treatment, whether there is fever or discharge.
2. Document. Standardized photos, lesion measurements, time of evolution, products injected and lots.
3. Suspect it when there is a late pattern, poor response to usual treatment and recurrence.
4. Do not improvise treatment. Avoid prolonged empirical regimens without a diagnosis.
5. Refer to an infectious disease physician or an appropriate service, with a clinical summary.
6. Cooperate with sample collection: the physician may request a specific culture and biopsy. Say that the suspicion includes mycobacteria, because a standard culture can be negative.
7. Report the event, when applicable. See adverse event reporting (NOTIVISA) and the notion of technovigilance.

What should you do about other patients?

A suspicious case is also a process alert. Review what was used and how: lot, solution, water, vial, environment, reprocessing. If there is more than one case linked to the same lot or the same period, the situation may amount to a safety incident and must be reported to the authorities, as the rules require. Keep traceability in order and talk to other patients treated in the same period, when indicated.

Everyday prevention is covered in biosafety in facial harmonization, sharps disposal and PGRSS and the pre-procedure checklist in facial harmonization.

How do you tell the patient?

Be transparent, without speculating and without blaming. The patient needs to know there is a hypothesis, what will be done to clarify it and who will follow the case.

Document the conversation in the patient record and, where appropriate, update the informed consent. The question of liability should be discussed with legal counsel and your professional board, if needed.

Does Harmy have a role?

Harmy does not diagnose or assess infection. It serves another part of care: the per-patient history stores sessions with date, marked areas and ml, which can help recall what was planned. The formal clinical record remains the patient record.

For the app flow, see how to use Harmy.

Review quiz

Atypical mycobacteria are rare, but this is the kind of diagnosis that only shows up for those who remember it. Recognizing the late, persistent pattern, referring early, documenting and reviewing the process is what keeps an isolated case from becoming a bigger problem.